Under Spanish law, when the first generic version of a medicament of reference (i.e. original medicament) is authorized, the setting of the price of the generic triggers the inclusion of the medicament of reference in the so-called “price reference system”, even if the generic is not launched onto the market until the patent protecting the medicament of reference expires. This has prompted the debate as to whether applying and obtaining a price may be objectionable.

On 16 November 2010, Commercial Court Number 5 of Barcelona handed down a judgment concluding that obtaining a price in these circumstances is an act of unfair competition since, even if the generic is not launched, the act of merely obtaining a price compromises the competitive position of the owner of the medicament of reference.


To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe here.

Kluwer IP Law